Literature DB >> 6605497

Behavioral correlations of dopamine receptor activation.

O Gershanik, R E Heikkila, R C Duvoisin.   

Abstract

According to the classification scheme of Kebabian and Calne, there are two types of dopamine (DA) receptors: D1 (activation of which causes increased cyclic AMP formation) and D2 (activation of which causes no increment in cyclic AMP). It is not clear what role the different receptors play in mediating motor behavior. Using drugs that act selectively at only one receptor site, we studied the effects of D1 and D2 receptor activation in two different models of parkinsonism--the rotating rat and the reserpinized mouse. Neither the D1 agonist nor the D2 agonist, given alone, could overcome reserpine akinesia, but together they restored locomotor activity. In rats with unilateral nigrostriatal lesions, both drugs induced a rotational response, each with a distinct temporal pattern. Pretreatment with alpha-methyl-paratyrosine (an inhibitor of DA synthesis) led to decrements in the rotational response induced by D2 agonists, but not that induced by D1 agonists. The mechanism by which these DA agonists induce motor activity is different; activation of both types of DA receptors seems to be necessary for normal motor behavior.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6605497     DOI: 10.1212/wnl.33.11.1489

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

Authors:  P A Löschmann; L A Smith; K W Lange; P Jähnig; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Postsynaptic bimodal effect of sulpiride on locomotor activity induced by pergolide in catecholamine-depleted mice.

Authors:  M Rubinstein; O Gershanik; F J Stefano
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.

Authors:  A M Zarkovsky; K S Cereska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

4.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.

Authors:  P Seeman; H B Niznik; H C Guan; G Booth; C Ulpian
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

5.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

6.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

7.  In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390.

Authors:  S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Evidence for postsynaptic dopamine agonist effects of B-HT 920 in the presence of the dopamine D-1 agonist SKF 38393.

Authors:  L T Meltzer; J N Wiley; A E Williams; T G Heffner
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

9.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

10.  Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.

Authors:  J Arnt; J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.